Strata Critical Medical Q2 Revenue Seen Falling 5.3%, Missing Own Guidance
SRTA sits 40% above its 52-week low of $3.675.
Summary
Strata Critical Medical is expected to report Q2 revenue of $67.05M, a 5.3% decline from last year and well below its own guidance of $71.5M-$72.9M. The consensus EPS estimate is $0.01. This follows a strong Q1 with 87% revenue growth, making the projected sequential drop notable. The company reports on August 4; the miss versus internal targets could pressure the stock despite a 'buy' consensus and $8.75 price target.
At the time of this announcement, SRTA was trading at $5.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $440.4M. The 52-week trading range was $3.68 to $6.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.